Cargando…
SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy
BACKGROUND: This study sought to assess the relationship between suppressor of cytokine signaling 3 (SOCS3) expression, SOCS3 promoter methylation status, and platinum-based chemotherapy responses in advanced non-small cell lung cancer (NSCLC) patients. METHODS: A total of 400 advanced NSCLC patient...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929795/ https://www.ncbi.nlm.nih.gov/pubmed/36819530 http://dx.doi.org/10.21037/atm-22-6065 |
_version_ | 1784888935319601152 |
---|---|
author | Zhang, Xiao-Ming Liu, Tian-Yang Li, Shi-Qi Han, Xin-Ai Song, Rui Wang, Jin-Hong |
author_facet | Zhang, Xiao-Ming Liu, Tian-Yang Li, Shi-Qi Han, Xin-Ai Song, Rui Wang, Jin-Hong |
author_sort | Zhang, Xiao-Ming |
collection | PubMed |
description | BACKGROUND: This study sought to assess the relationship between suppressor of cytokine signaling 3 (SOCS3) expression, SOCS3 promoter methylation status, and platinum-based chemotherapy responses in advanced non-small cell lung cancer (NSCLC) patients. METHODS: A total of 400 advanced NSCLC patients with inoperable disease were enrolled in this study. All the patients underwent platinum-based chemotherapy treatment, and the clinical and prognostic outcomes of these patients were analyzed. The SOCS3 protein expression and SOCS3 promoter methylation status of the tumor tissues in these patients were also tested by immunohistochemistry and polymerase chain reaction (PCR), respectively. In addition, we knocked down SOCS3 expression via small-interfering RNA (siRNA) in the lung cancer cell lines and conducted in vitro analyses to examine cell viability and apoptosis. RESULTS: Patients with higher expression levels of SOCS3 were found to have a lower average tumor stage, higher average tumor differentiation, and higher rates of positive chemotherapy responses than those with lower expression levels of SOCS3. SOCS3 promoter methylation was also found to be correlated with chemotherapy responses in these patients. In the prognostic analyses, only SOCS3 expression, but not SOCS3 promoter methylation, was found to be predictive of outcomes in advanced NSCLC patients. We also found that the pro-apoptotic effects of SOCS3 were mediated by the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathways in the lung cancer cells. CONCLUSIONS: Currently, there is a lack of reliable biomarkers for predicting the responses of NSCLC patients to chemotherapy. Our results may aid in clinical evaluations of NSCLC patients. |
format | Online Article Text |
id | pubmed-9929795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-99297952023-02-16 SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy Zhang, Xiao-Ming Liu, Tian-Yang Li, Shi-Qi Han, Xin-Ai Song, Rui Wang, Jin-Hong Ann Transl Med Original Article BACKGROUND: This study sought to assess the relationship between suppressor of cytokine signaling 3 (SOCS3) expression, SOCS3 promoter methylation status, and platinum-based chemotherapy responses in advanced non-small cell lung cancer (NSCLC) patients. METHODS: A total of 400 advanced NSCLC patients with inoperable disease were enrolled in this study. All the patients underwent platinum-based chemotherapy treatment, and the clinical and prognostic outcomes of these patients were analyzed. The SOCS3 protein expression and SOCS3 promoter methylation status of the tumor tissues in these patients were also tested by immunohistochemistry and polymerase chain reaction (PCR), respectively. In addition, we knocked down SOCS3 expression via small-interfering RNA (siRNA) in the lung cancer cell lines and conducted in vitro analyses to examine cell viability and apoptosis. RESULTS: Patients with higher expression levels of SOCS3 were found to have a lower average tumor stage, higher average tumor differentiation, and higher rates of positive chemotherapy responses than those with lower expression levels of SOCS3. SOCS3 promoter methylation was also found to be correlated with chemotherapy responses in these patients. In the prognostic analyses, only SOCS3 expression, but not SOCS3 promoter methylation, was found to be predictive of outcomes in advanced NSCLC patients. We also found that the pro-apoptotic effects of SOCS3 were mediated by the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathways in the lung cancer cells. CONCLUSIONS: Currently, there is a lack of reliable biomarkers for predicting the responses of NSCLC patients to chemotherapy. Our results may aid in clinical evaluations of NSCLC patients. AME Publishing Company 2023-01-31 2023-01-31 /pmc/articles/PMC9929795/ /pubmed/36819530 http://dx.doi.org/10.21037/atm-22-6065 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Zhang, Xiao-Ming Liu, Tian-Yang Li, Shi-Qi Han, Xin-Ai Song, Rui Wang, Jin-Hong SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy |
title | SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy |
title_full | SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy |
title_fullStr | SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy |
title_full_unstemmed | SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy |
title_short | SOCS3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy |
title_sort | socs3 protein expression predicts the responses of advanced non-small cell lung cancer patients to platinum-based chemotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929795/ https://www.ncbi.nlm.nih.gov/pubmed/36819530 http://dx.doi.org/10.21037/atm-22-6065 |
work_keys_str_mv | AT zhangxiaoming socs3proteinexpressionpredictstheresponsesofadvancednonsmallcelllungcancerpatientstoplatinumbasedchemotherapy AT liutianyang socs3proteinexpressionpredictstheresponsesofadvancednonsmallcelllungcancerpatientstoplatinumbasedchemotherapy AT lishiqi socs3proteinexpressionpredictstheresponsesofadvancednonsmallcelllungcancerpatientstoplatinumbasedchemotherapy AT hanxinai socs3proteinexpressionpredictstheresponsesofadvancednonsmallcelllungcancerpatientstoplatinumbasedchemotherapy AT songrui socs3proteinexpressionpredictstheresponsesofadvancednonsmallcelllungcancerpatientstoplatinumbasedchemotherapy AT wangjinhong socs3proteinexpressionpredictstheresponsesofadvancednonsmallcelllungcancerpatientstoplatinumbasedchemotherapy |